Galectin

OTX008 is a selective inhibitor of galectin-1.

GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.

Galectin-13 Human Recombinant

Galectin-7 Human Recombinant

Galectin-8 Human Recombinant

Galectin-2 Mouse Recombinant

Galectin-7 Mouse Recombinant

Galectin-8 Mouse Recombinant

Galectin-1 Mouse Recombinant

Galectin-4 Mouse Recombinant

Galectin-3 Mouse Recombinant

Galectin-1 Human Recombinant

Galectin-9 Mouse Recombinant

Galectin-3 Human Recombinant

Galectin-7 Human Recombinant, His Tag

Galectin-4 Human Recombinant

Galectin-3 Human Recombinant, His Tag

Galectin-9 Human Recombinant

Galectin-2 Human Recombinant

Galectin-8 Human Recombinant, His Tag

Galectin-16 Human Recombinant

Charcot-Leyden Crystal Protein Human Recombinant

Olitigaltin is a synthetic inhibitor of galectin-3, demonstrating a high binding affinity with a Kd value of 68 nM. This compound exhibits significantly lower affinity for galectin-1 and galectin-7, with Kd values of 0.22 μM and 38 μM, respectively. Olitigaltin is valuable for research applications investigating the role of galectin-3 in various biological processes, including inflammation, fibrosis, and cancer progression.

Thiodigalactoside is a potent inhibitor of galectins, specifically targeting GAL1 and GAL3 with Kd values of 24 μM and 49 μM, respectively. As a non-metabolizable disaccharide, it demonstrates significant anti-inflammatory and anti-cancer properties. Additionally, Thiodigalactoside has been shown to effectively reduce body weight gain in diet-induced obese rat models, making it a valuable tool for studying metabolic disorders and galectin-related diseases.

Selvigaltin (GB1211) is an orally active inhibitor of galectin-3, exhibiting a potent IC50 of 12 nM in rabbit models. This compound demonstrates significant anti-tumor activity by effectively reducing galectin-3 levels in the liver, which leads to decreased biomarkers associated with liver function, inflammation, and fibrosis. Additionally, Selvigaltin downregulates the expression of key inflammatory and fibrotic markers, such as IL6, TGFβ3, SNAI2, and collagen, while also restoring T-cell activity, thereby impeding tumor growth and metastasis. It serves as a valuable tool for research into therapeutic strategies targeting galectin-3 related disorders.

β-Lactose is a disaccharide that serves as an inhibitor of galectin-3, a protein involved in various biological processes, including cell adhesion and immune response. Its ability to modulate galectin-3 activity makes it a valuable tool in research pertaining to cancer, inflammation, and fibrosis. Additionally, β-lactose can be utilized as a substrate in studies of lactose metabolism and as a model compound for investigating carbohydrate-protein interactions.

Galectin-3 antagonist 1 is a specific inhibitor of Galectin-3, exhibiting a Kd value of 5.3 μM. This compound also demonstrates binding affinities to other galectins, with Kd values of 250 μM for Gal-4N, 18 μM for Gal-4C, and 450 μM for Gal-8C. It serves as a valuable tool for investigating the role of Galectin-3 in various biological processes and its implications in disease states, making it suitable for research in cancer, inflammation, and fibrosis.

4,5-Dibromo-2-pyrrolic acid is an immunosuppressive compound that acts by inhibiting the proliferative response of splenocytes. This compound has been shown to significantly reduce the activation of immune cells in response to suboptimal concentrations of the mitogen concanavalin A (Con A). Its primary applications include research in immune regulation and the study of immunosuppressive mechanisms.

Galectin-8N-IN-1 is a selective inhibitor targeting galectin-8N, exhibiting a Kd value of 1.8 μM. This compound serves as a valuable ligand for galectin-8N studies and plays a critical role in researching immune system mechanisms. Its potent inhibition of galectin-8N makes it an essential tool for exploring immune modulation and related biochemical pathways.

GB1908 is a selective oral inhibitor of galectin-1, demonstrating Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. This compound exhibits over 50-fold selectivity for galectin-1 compared to galectin-3. GB1908 serves as a valuable tool in the investigation of lung cancer and related therapeutic strategies, facilitating research into the role of galectin-1 in tumor progression and immune modulation.

Thiobis-β-Galactose-propyne serves as a versatile click chemistry reagent with an alkyne functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Primarily, it acts as a multivalent inhibitor of galectin-3 (Gal-3), a protein implicated in various metabolic processes associated with cancer progression. This compound is suitable for applications in biochemical research focused on galectin-3-related pathways and provides a valuable tool for the development of targeted therapeutic strategies.

DB21 is a Galectin-1 antagonist that functions as an allosteric inhibitor of galectin-1 binding to cell surface glycans. This dibenzofuran-conjugated peptidomimetic demonstrates significant inhibition of angiogenesis and tumor growth in models of melanoma, lung adenocarcinoma, and ovarian cancer. Its ability to disrupt galectin-1 interactions positions DB21 as a valuable tool for cancer research and therapeutic development.

Galectin-3/Galectin-8-IN-1 is a dual inhibitor targeting the C-terminal domains of Galectin-3 and Galectin-8, exhibiting Kd values of 4.12 μM and 6.04 μM, respectively. This compound effectively hinders migration in MRC-5 lung fibroblast cells, highlighting its potential role in modulating cellular processes. Galectin-3/Galectin-8-IN-1 is applicable in cancer research and studies focusing on tissue fibrosis, offering insights into therapeutic strategies for these conditions.

GB2095 is a selective inhibitor of galectin-3, demonstrating strong binding affinity with human (KD = 0.036 μM) and mouse (KD = 0.35 μM) variants. This compound exhibits significant anti-tumor activity in syngeneic mouse models, specifically for breast and melanoma cancers. GB2095 is valuable for research applications aimed at understanding the role of galectin-3 in cancer progression and therapeutic interventions.

Galectin-4-IN-3 is a selective inhibitor of Galectin 4C, exhibiting a Kd of 160 μM. This compound is valuable for studies investigating the role of Galectins in cell-cell adhesion, immune response regulation, and cancer progression. Researchers can utilize Galectin-4-IN-3 to explore potential therapeutic strategies targeting Galectin-mediated pathways in various disease contexts.

Galectin-8-IN-2 is a selective inhibitor of galectin-8N, a member of the galectin family implicated in various biological processes. This compound exhibits significant inhibitory activity, making it a valuable tool for investigating galectin-mediated pathways and their roles in disease mechanisms. It is particularly useful for research focused on cancer, inflammation, and immune response modulation.

Galectin-8-IN-1 is a selective ligand targeting the N-terminal domain of galectin-8 (galectin-8N), exhibiting a dissociation constant (Kd) of 48 μM. This compound demonstrates a 15-fold selectivity over galectin-3, as well as significantly enhanced selectivity against other mammalian galectins. Galectin-8-IN-1 is valuable for research applications focused on galectin biology, immune responses, and cell signaling pathways.

Galectin-4-IN-2 is a potent inhibitor of galectin-4C, exhibiting a dissociation constant of 1.6 mM. This compound is valuable for studies investigating the role of galectin-4 in various biological processes, including cell adhesion, immune response, and cancer biology. Research applications include elucidating the mechanisms of galectin-mediated pathways and exploring therapeutic strategies targeting galectin proteins in disease models.

Galectin-3-IN-4 is a selective carboxamide inhibitor targeting galectin-3, with an IC50 of 21 nM for human galectin-3 and 167 nM for mouse galectin-3. This compound demonstrates significant selectivity, showing much higher IC50 values of 1580 nM and 2750 nM for human galectin-1 and galectin-9, respectively. Galectin-3-IN-4 is orally bioavailable, making it a valuable tool for research into the role of galectin-3 in various biological processes, including cancer, inflammation, and fibrosis.

Galectin-3-IN-2 is a potent multivalent inhibitor of galectin-3 (Gal-3), exhibiting an IC50 value of 8.3 μM. Galectin-3 is involved in various cancer-related metabolic processes, making this compound valuable for research into cancer biology and therapeutic development. Its application as a Gal-3 inhibitor allows for the exploration of its role in tumor progression, metastasis, and immune response modulation.

Galectin-3-IN-6 is a potent inhibitor of galectin-3, displaying an IC50 of 12 nM against human galectin-3 and 12.6 nM against the mutant murine galectin-3 (V160A), along with a Kd of 13 nM. This compound effectively reduces markers of liver fibrosis, including type I collagen and α-smooth muscle actin, in murine models of acute liver injury and fibrosis. Galectin-3-IN-6 serves as a valuable tool for investigating the mechanisms and potential therapies for acute liver injury and related fibrotic conditions.

SNAP 398299 is a selective antagonist of the Galectin-3 (Gal3) receptor. This compound has demonstrated potential anxiolytic and antidepressant effects by partially reversing the neuropeptide galanin-induced inhibition of dorsal raphe neuronal firing as well as the galanin-induced hyperpolarizing current. Its unique mechanism makes SNAP 398299 a valuable tool for researching the roles of galectin in neurobiology and potential therapeutic interventions for mood disorders.

Galectin-3 antagonist 2 is a compound that specifically targets galectin-3, a β-galactoside-binding lectin. This antagonist is known to inhibit the activity of galectin-3, which has been implicated in promoting the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and contributing to drug resistance in this malignancy. It is utilized in research applications focused on cancer biology, particularly in understanding the mechanisms of leukemogenesis and the development of therapeutic strategies for leukemia.

Galectin-3-IN-3 is a selective inhibitor of galectin-3, exhibiting potent activity with IC50 values of 11 nM for mouse galectin-3 and 84 nM for human galectin-3. This compound serves as a valuable tool for studying the role of galectin-3 in various biological processes, including tumor progression, inflammation, and fibrosis. Its oral bioavailability allows for convenient administration in preclinical models, facilitating research in therapeutic applications targeting galectin-3-related pathologies.

GB1490 is a potent galectin-1 inhibitor, exhibiting a Kd value of 0.4 μM. Additionally, it shows inhibitory activity against galectin-3 with a Kd of 2.7 μM. This compound is primarily utilized in research to investigate the role of galectins in various biological processes, including cancer progression and immune response modulation. Its selectivity and potency make it a valuable tool in studies aimed at understanding galectin-related pathways.

Galectin-8N-IN-2 is a selective inhibitor of Galectin-8N, exhibiting a Ki value of 74 µM. This compound is essential for investigating the role of Galectin-8N in biological processes, particularly in modulating cell adhesion, immune responses, and tumor progression. Its inhibitory action facilitates research into therapeutic strategies targeting galectins in cancer and autoimmune diseases.